Shani Paluch‐Shimon
A5001211980- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Cancer Treatment and Pharmacology
- Reproductive Biology and Fertility
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- DNA Repair Mechanisms
- Nutrition, Genetics, and Disease
- Ovarian cancer diagnosis and treatment
- Global Cancer Incidence and Screening
- MicroRNA in disease regulation
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Family Support in Illness
- CRISPR and Genetic Engineering
- Prenatal Screening and Diagnostics
- Cancer survivorship and care
- Economic and Financial Impacts of Cancer
- Assisted Reproductive Technology and Twin Pregnancy
- Multiple and Secondary Primary Cancers
- Monoclonal and Polyclonal Antibodies Research
Hebrew University of Jerusalem
2021-2025
Hadassah Medical Center
2021-2025
Hadassah Academic College
2020-2025
Sheba Medical Center
2011-2022
Shaare Zedek Medical Center
2007-2022
Texas Oncology
2021
Baylor University Medical Center
2021
University of Sheffield
2020
Virginia Cancer Specialists
2018
Istituto Oncologico Veneto
2018
The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) negative human epidermal growth factor 2 (HER2).In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy safety selective CDK4/6 inhibitor ribociclib combined with letrozole first-line treatment 668 postmenopausal women HR-positive, HER2-negative recurrent metastatic who had...
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy in combination with fulvestrant women hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer previously treated endocrine therapy. Methods MONARCH 3 is double-blind, randomized phase III study of abemaciclib or placebo plus nonsteroidal aromatase inhibitor 493 postmenopausal HR-positive, HER2-negative who had no prior systemic therapy the...
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic (MBC) [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text PDF PubMed Scopus (252) Google Scholar]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years 5-year only ∼25% [2.Cardoso Spence D. Mertz S. et al.Global analysis...
BackgroundThe phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. Here, we report updated efficacy safety data, together exploratory biomarker analyses, from the study.Patients methodsA total of 668 postmenopausal women HR+,...
Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line treatment patients with mTNBC.
Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists.
The BRCA1/2 proteins are involved in regulation of cellular proliferation by DNA damage repair via homologous recombination. Therefore, mutation carriers with pancreatic cancer may have distinct biologic outcomes. Patients BRCA1/2-associated ductal adenocarcinoma (PDAC) diagnosed between January 1994 and December 2012 were identified from databases at three participating institutions. Clinical data collected. Disease-free survival overall (OS) analysed. Overall, 71 patients PDAC BRCA1...
Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free (DRFS) hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of prespecified primary outcome analysis an additional analysis.This global, phase III,...
Highlights•This phase III trial evaluated abemaciclib + NSAI versus placebo as initial therapy for HR+, HER2− ABC.•Addition of to an resulted in numerically longer OS; however, statistical significance was not reached.•Absolute improvement median OS clinically meaningful (ITT: 13.1 months; sVD: 14.9 months).•The previously demonstrated PFS benefit with the addition sustained (median 14.3 delayed subsequent receipt chemotherapy 16.1 months).AbstractBackgroundIn MONARCH 2, fulvestrant...
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at last two ABC conferences (ABC 6 in 2021, virtual, and 7 2023, Lisbon, Portugal), organized by Global Alliance. It provides main recommendations on how to best manage patients with advanced breast cancer (inoperable locally or metastatic), of all subtypes, as well palliative supportive care. These are based available evidence expert opinion when a higher level is lacking. Each guideline...
1008 Background: In KEYNOTE-012, pembro showed durable activity and manageable safety in patients (pts) with PD-L1+ mTNBC. Cohort A of KEYNOTE-086 (NCT02447003) examined the efficacy/safety previously treated mTNBC, regardless PD-L1 expression. Methods: Pts centrally confirmed ≥1 prior chemotherapy for metastatic disease, ECOG PS 0-1 had 200 mg Q3W up to 24 mo; imaging q 9 wk first 12 mo, then wk. Clinically stable pts PD could remain on until next assessment. Primary endpoints: ORR (RECIST...
Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is definitive. From September 2012-March 2013, 212 evaluable ER+ early BC, <37 years at diagnosis, from 5 regions (Europe/US/Canada/Middle-East/Australia) answered a survey fertility concerns, desire interest study of endocrine therapy (ET) interruption...